BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12829134)

  • 21. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields.
    Bradley JD; Wahab S; Lockett MA; Perez CA; Purdy JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):342-7. PubMed ID: 12738307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
    Kong FM; Hayman JA; Griffith KA; Kalemkerian GP; Arenberg D; Lyons S; Turrisi A; Lichter A; Fraass B; Eisbruch A; Lawrence TS; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1075-86. PubMed ID: 16647222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
    Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.
    Le QT; Loo BW; Ho A; Cotrutz C; Koong AC; Wakelee H; Kee ST; Constantinescu D; Whyte RI; Donington J
    J Thorac Oncol; 2006 Oct; 1(8):802-9. PubMed ID: 17409963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
    Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
    Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
    Lee CB; Stinchcombe TE; Moore DT; Morris DE; Hayes DN; Halle J; Rosenman JG; Rivera MP; Socinski MA
    J Thorac Oncol; 2009 Jan; 4(1):74-9. PubMed ID: 19096310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rhubarb extract on radiation induced lung toxicity via decreasing transforming growth factor-beta-1 and interleukin-6 in lung cancer patients treated with radiotherapy.
    Yu HM; Liu YF; Cheng YF; Hu LK; Hou M
    Lung Cancer; 2008 Feb; 59(2):219-26. PubMed ID: 17870203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
    Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
    J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose escalation for non-small cell lung cancer using conformal radiation therapy.
    Robertson JM; Ten Haken RK; Hazuka MB; Turrisi AT; Martel MK; Pu AT; Littles JF; Martinez FJ; Francis IR; Quint LE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1079-85. PubMed ID: 9169816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
    J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
    Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.